Strategic Advisory Team
BPP has fostered strategic advisory relationships with key visionaries, opinion and thought leaders from across pharma, the biotechnology industry, medical practice, and academic research to ensure that we are driving novel approaches for the rapid advance of innovation in the delivery of safe and cost-effective therapeutics, important diagnostics and new technologies in research, clinical and regulatory practices in the CNS.
 | Ramon Diaz-Arrastia, MD, PhD Presidential Professor of Neurology, Penn Medicine Assoc Director for Clinical Research, Center for Neurodegeneration and Repair, Penn Medicine Director of Traumatic Brain Injury Clinical Research Center, Penn Medicine TRACK-TBI Executive Committee BPP’s Principal Investigator in Clinical Study of neuroinflammation |
 | Micheal Geschwind, MD, PhD Professor of Neurology, UCSF Memory and Aging Center Specialist in neurodegenerative disorders, including progressive dementias, prion disease BPP’s advisor on prion disease models, biomarkers, outcomes |
 | John Kelley Chairman and Chief Executive Officer, CereScan and CereHealth Member, Forbes Technology Council Chairman, President, and Chief Executive Officer of McDATA Corporation BPP and CereHealth have formed a strategic alliance to advance CereMetrix, an FDA-cleared data analytics platform, to evaluate and correlate outcome measures utilized in CNS clinical trials (including the BPP clinical trial) |
 | Philip Harvey, PhD Professor of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine. Formerly professor of Psychiatry at Mt. Sinai School of Medicine and Chief Psychologist at Mt. Sinai Hospital. Developing composite clinical measure for BPP’s clinical trial in neuroinflammation Further advising BPP on link between depression and Alzheimer’s Disease |